Latest News
Prime Medicine, Inc.
- Prime Editing Rewrites DNA Inside a Patient’s Body for the First Time
- Prime Medicine launches first in-body prime editing trial for Wilson disease
- Prime Medicine (Nasdaq:PRME) - Stock Analysis
- Prime Medicine Stock Rallies Nearly 26% in a Month: Here's Why
- Prime Medicine doses first patient in prime-editing trial for H1069Q Wilson disease
- Prime Medicine Announces First Patient Dosed in Global Phase 1/2 Clinical Trial of PM577a for H1069Q-Mutated Wilson Disease
- Prime Medicine receives FDA clearance for PM647 in alpha-1 antitrypsin deficiency
- Citizens reiterates Prime Medicine stock rating on gene editing capabilities
- FDA clears Prime Medicine's PM647 in vivo gene-editing therapy for alpha-1 antitrypsin deficiency
- Prime Medicine stock jumps 8% after FDA clears PM647 trial
- Prime Medicine: A Buy Due To BLA Filing H1 '27 And In Vivo Therapy Development (PRME)
- Prime Medicine Announces U.S. FDA Clearance of
Headlines from the last 30 days, linking to the original publishers. See all market news →